A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.
Status:
Withdrawn
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, placebo controlled, four way crossover, in which the the effect
of GSK2190915 on the QTc interval is assessed. Healthy subjects will recieve a 5 day course
of each of the following; oral placebo, GSK2190915 100mg, GSK2190915 1000mg and moxifloxacin
400mg (single dose) with a weeks washout prior to starting the next course. Key assessments
include a 12- lead electrocardiogram and pharmacokinetic testing. Safety will be assessed by
blood pressure, heart rate, clinical laboratory safety tests and collection of adverse events
.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination